40 results on '"Gormley, Nicole J."'
Search Results
2. Data from The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990–2018
3. FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
4. Supplementary Figure 1 from The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990–2018
5. The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990–2018
6. Supplementary Tables S1-S3 from The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology
7. Supplementary Table S2: Clinical trials in myeloma using MRD assessments from The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
8. Supplementary Figures S1 and S2: Association of MRD with survival outcomes in myeloma patients from The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
9. Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective
10. Recombinant Human Factor VIIa for Alveolar Hemorrhage Following Allogeneic Stem Cell Transplantation
11. Minimal Residual Disease as a Potential Surrogate End Point—Lingering Questions
12. FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma
13. Minimal Residual Disease (MRD) Data in Hematologic Malignancy Drug Applications and Prescribing Information: FDA Analysis
14. FDA Oncology Center of Excellence Review of Real World Data Submissions Supporting Drug Development in Hematologic Malignancies
15. Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
16. Perspectives on Drug Development in Multiple Myeloma-Looking forward to 2025
17. FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
18. Minimal residual disease in Myeloma: Application for clinical care and new drug registration
19. Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples
20. The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology
21. FDA Analysis of Screen Failures By Race in Clinical Trials of Acute Myeloid Leukemia
22. FDA Analysis of Survival Outcomes in Older Adults with Relapsed-Refractory Multiple Myeloma (RRMM) Treated with Novel Drug Regimens
23. FDA Analysis: Impact of Body Mass Index (BMI) on Outcomes in Relapsed-Refractory Multiple Myeloma
24. Effect of Cyclosporine Inhalation Solution (CIS) on Lung Function and Inflammatory Biomarkers in Patients with Hematopoietic Stem Cell Transplant (HSCT) Associated Bronchiolitis Obliterans Syndrome (BOS)
25. Immunotherapy Combinations in Multiple Myeloma — Known Unknowns
26. FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
27. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy
28. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
29. Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma
30. Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.
31. The rising incidence of intentional ingestion of ethanol-containing hand sanitizers
32. Co-Infusion of Allogeneic Cord Blood with Haploidentical CD34+ Cells Improved Transplant Outcome for Patients with Severe Aplastic Anemia Undergoing Cord Blood Transplantation
33. In Vitro Assessment of Tolerance and Rejection Occurring After Co-Transplantation of Allogeneic Umbilical Cord Blood and Haploidentical CD34+ Cells as Treatment for Severe Aplastic Anemia
34. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
35. FDA Approval Summary: Teclistamab - A Bispecific CD3 T-cell Engager for Patients with Relapsed or Refractory Multiple Myeloma.
36. FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-cell Lymphomas.
37. Improving Collection and Analysis of Overall Survival Data.
38. FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma.
39. Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.
40. Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.